Codiak BioSciences, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Codiak BioSciences, Inc. reported Net Income (Loss) Available to Common Stockholders, Basic of -$19.28 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-11-03
- Codiak BioSciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$19.28M.
- Codiak BioSciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$6.78M.
- Codiak BioSciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$8.03M.
- Codiak BioSciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was $16.66M.
- Codiak BioSciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$37.16M.
- Codiak BioSciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$102.50M.
- Codiak BioSciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$91.66M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$19.28M 10-Q · filed 2022-11-03 | -$26.05M derived: sum of 2 quarters · filed 2022-11-03 | -$34.08M 10-Q · filed 2022-11-03 | -$17.42M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | -$6.78M 10-Q · filed 2022-08-04 | -$14.80M 10-Q · filed 2022-08-04 | $1.86M derived: sum of 3 quarters · filed 2022-08-04 | -$19.84M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-03-31 | -$8.03M 10-Q · filed 2022-05-05 | $8.63M derived: sum of 2 quarters · filed 2022-05-05 | -$13.07M derived: sum of 3 quarters · filed 2022-11-03 | -$34.88M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-12-31 | $16.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$5.04M derived: sum of 2 quarters · filed 2022-11-03 | -$26.85M derived: sum of 3 quarters · filed 2022-11-03 | -$37.16M 10-K · filed 2022-03-10 |
| 2021-09-30 | -$21.70M 10-Q · filed 2022-11-03 | -$43.51M derived: sum of 2 quarters · filed 2022-11-03 | -$53.82M 10-Q · filed 2022-11-03 | -$72.31M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$21.81M 10-Q · filed 2022-08-04 | -$32.12M 10-Q · filed 2022-08-04 | -$50.61M derived: sum of 3 quarters · filed 2022-08-04 | -$89.36M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$10.31M 10-Q · filed 2022-05-05 | -$28.80M derived: sum of 2 quarters · filed 2022-05-05 | -$67.55M derived: sum of 3 quarters · filed 2022-05-05 | -$86.88M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$18.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$57.24M derived: sum of 2 quarters · filed 2022-03-10 | -$76.58M derived: sum of 3 quarters · filed 2022-03-10 | -$102.50M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$38.75M 10-Q · filed 2021-11-04 | -$58.08M derived: sum of 2 quarters · filed 2021-11-04 | -$84.00M 10-Q · filed 2021-11-04 | -$109.10M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$19.33M 10-Q · filed 2021-08-05 | -$45.25M 10-Q · filed 2021-08-05 | -$70.35M derived: sum of 3 quarters · filed 2021-08-05 | -$94.46M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$25.92M 10-Q · filed 2021-05-06 | -$51.01M derived: sum of 2 quarters · filed 2021-05-06 | -$75.13M derived: sum of 3 quarters · filed 2021-05-06 | |
| 2019-12-31 | -$25.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$49.21M derived: sum of 2 quarters · filed 2021-03-17 | -$91.66M 10-K · filed 2021-03-17 | |
| 2019-09-30 | -$24.12M 10-Q · filed 2020-11-19 | -$66.57M 10-Q · filed 2020-11-19 |